GlassScriptPhysician profile
Patricia Wong
NPI 1659433936
$29,039.32
in general payments reported to CMS, 2019-2025
31 companies · $2,531 in 2025
The $2,531 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,680 · 2020: $5,802 · 2021: $1,158 · 2022: $1,497 · 2023: $2,086 · 2024: $9,286 · 2025: $2,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,900 · Food and Beverage: $4,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,900.00 |
| Food and Beverage | $4,001.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,884.89 | 2019-2024 | Linzess, Skyrizi, Rinvoq |
| Phathom Pharmaceuticals, INC. | $10,346.19 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,841.75 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $972.32 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $505.62 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $380.81 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $301.16 | 2019-2023 | |
| Gilead Sciences, INC. | $247.13 | 2019-2023 | Epclusa |
| Nestle Healthcare Nutrition INC. | $184.10 | 2021-2023 | |
| Genzyme Corporation | $182.16 | 2022-2024 | |
| Ucb, INC. | $139.00 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $125.84 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $124.10 | 2022-2023 | Sucraid |
| Boston Scientific Corporation | $114.98 | 2020 | |
| Ardelyx, INC. | $94.99 | 2023-2024 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $86.79 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $75.70 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $74.73 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $56.46 | 2020-2024 | Injectafer |
| Dynavax Technologies Corporation | $37.08 | 2019-2020 | |
| Shionogi INC | $35.93 | 2019 | |
| Allergan, INC. | $33.89 | 2019 | |
| Lilly USA, LLC | $30.07 | 2024 | Omvoh |
| Mallinckrodt Hospital Products INC. | $28.77 | 2023 | Terlivaz |
| Shire North American Group INC | $23.91 | 2019 | |
| Capsovision, INC. | $23.69 | 2024 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $20.64 | 2024 | |
| Sandoz INC. | $19.06 | 2024 | Hyrimoz |
| Braintree Laboratories, INC. | $17.87 | 2019 | |
| Alfasigma USA, INC. | $16.86 | 2020 | |
| Redhill Biopharma INC. | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.